| Literature DB >> 36175614 |
Karine Morcel1, Philippe Merviel2, Diane Pertuisel1, Pandora James1, Sarah Bouée1, Mathilde Le Guillou1, Jean-Jacques Chabaud1, Sylvie Roche1, Hortense Drapier3, Aurore Perrin3, Damien Beauvillard3.
Abstract
Many studies failed to show a predictive impact of AMH levels on the chances of pregnancy; however, acceptable pregnancy rates for young women with low AMH levels were observed in IVF + / - ICSI. The objectives of this retrospective study were to evaluate the clinical pregnancy and live birth rates in the first IVF + / - ICSI cycle in women under 38 years old with AMH level < 1.2 ng/ml and to determine the arguments for care. We classified the women into three groups: group A: AMH < 0.4 ng/ml (n: 86); group B: AMH: 0.4 to 0.8 ng/ml (n: 90); and group C: AMH > 0.8 to < 1.2 ng/ml (n: 92). We recorded data on the patients' characteristics, stimulation cycles, embryo cultures, and ongoing pregnancies. No difference was observed between the three groups for the number of embryos transferred, the clinical pregnancy, and the live birth rates (LBR) per embryo transfer (LBR/transfer: 24.1% in group A, 25.9% in group B, and 28.1% in group C). The young age of the women reassures about the oocyte quality, but a low level of AMH may raise concerns about a lower quantitative oocyte yield, leading to accelerated management of the couple in IVF + / - ICSI.Entities:
Keywords: Anti-Müllerian hormone; In vitro fertilization/intracytoplasmic sperm injection; Live birth; Predictive factors; Pregnancy
Year: 2022 PMID: 36175614 DOI: 10.1007/s43032-022-01091-x
Source DB: PubMed Journal: Reprod Sci ISSN: 1933-7191 Impact factor: 2.924